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ABSTRACT 55 
Earlier studies have indicated an important role for cerebral blood flow in the 56 
pathophysiology of central sleep apnea (CSA) at high altitude, but were not decisive. 57 
To test the hypothesis that pharmacologically altering cerebral blood flow (CBF) 58 
without altering arterial blood gas (ABGs) values would alter the severity of CSA at 59 
high altitude, we studied 11 healthy volunteers. (8M, 3F; 31±7 years) in a 60 
randomized placebo-controlled single-blind study at 5,050 metres in Nepal. 61 
CBF was increased by intravenous (iv) acetazolamide (Az; 10mg/kg) plus iv 62 
dobutamine (Dob) infusion (2-5 ug/kg/min) and reduced by oral indomethacin (Indo; 63 
100mg).  ABG samples were collected and ventilatory responses to hypercapnia 64 
(HCVR) and hypoxia (HVR) were measured by rebreathing and steady-state 65 
techniques before and after drug/placebo.  Duplex ultrasound of blood flow in the 66 
internal carotid and vertebral arteries was used to measure global CBF.  The initial 3-67 
4 hours of sleep were recorded by full polysomnography.  Iv Az+Dob increased 68 
global CBF by 37±15% compared to placebo (P<0.001), whereas it was reduced by 69 
21±8% by oral Indo (P<0.001).  ABGs and HVR were unchanged in both 70 
interventions.  HCVR was reduced by 28%±43% (P=0.1) during iv Az±Dob 71 
administration and was elevated by 23%±30% (P=0.05) by Indomethacin.  During iv 72 
Az+Dob, the CSA index fell from 140±45 (control night) to 48±37 events/hour of 73 
sleep (P<0.001).  Oral Indo had no significant effect on CSA.  We conclude that 74 
increasing cerebral blood flow reduced the severity of CSA at high altitude; the likely 75 
mechanism is via a reduction in the background stimulation of central 76 
chemoreceptors. 77 
Key Words:  Central sleep apnea; Cerebral blood flow; Ventilatory responses; High 78 
altitude. 79 
80 
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NEW AND NOTEWORTHY 81 
This work is significant because it shows convincingly for the first time in healthy 82 
volunteers, that increasing cerebral blood flow will reduce the severity of CSA in a 83 
high altitude model, without the potentially confounding effects of altering PaCO2 or 84 
the ventilatory response to hypoxia. 85 
 The proposed mechanism of action is that of increasing the removal of locally 86 
produced CO2 from the central chemoreceptors, causing the reduction in 87 
hypercapnic ventilatory response, hence reducing loop gain. 88 
  89 
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INTRODUCTION 90 
 Following ascent to high altitude by otherwise healthy individuals, CSA during 91 
sleep is almost universal, occurring in >90% of people above 5,000m.(7)  92 
Experiments at high altitude provide insight into the mechanisms underlying the 93 
pathogenesis of CSA, as well as potential therapeutic opportunities.  The common 94 
trigger to both CSA in heart failure and high altitude exposure is transient reduction 95 
in the partial pressure of arterial carbon dioxide (PaCO2) (12) below the apneic 96 
threshold during light sleep.(11)  The magnitude of the required PaCO2 reduction to 97 
initiate the CSA depends on  the awake values, the ventilatory response to PaCO2 98 
below eupnea and the position of the iso-metabolic line.(11, 30)  Other possible 99 
contributing factors, which have not been investigated extensively, especially 100 
following ascent to high altitude, are breathing pattern and cerebral blood flow (CBF), 101 
which are closely linked by the PaCO2.(11, 32)  The effects of PaCO2 on CBF 102 
provide an important protective mechanism which serves to minimize changes in 103 
brain [H+], thereby stabilizing the breathing pattern in the face of perturbations in 104 
PaCO2.(18, 32)  105 
Hypocapnia normally causes marked cerebral vasoconstriction and reduces 106 
CBF, thus attenuating the fall in brain tissue PCO2 relative to that of PaCO2(16).  107 
Accordingly, ventilatory inhibition in response to reduced PCO2 will be lessened, 108 
because of the attenuated decrease in [H+] stimulus to central chemoreceptors.  In 109 
addition, ascent to high altitude increases ventilatory responses to hypercapnia and 110 
hypoxia (6), which will likely cause greater breathing instability due to increases in 111 
ventilatory ‘loop gain’.(3)  This has even greater significance during sleep, when 112 
PaCO2 becomes critical in regulating the breathing pattern in the absence of the 113 
wakefulness drive to breathe.(13) 114 
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The PCO2 in the brain is higher than PaCO2; thus perfusion at the level of 115 
central chemoreceptors affects the strength of the locally produced (CO2/H+) 116 
stimulus. 117 
It is established that CBF falls at sleep onset in healthy individuals.(18) In a 118 
previous study, in a small number of subjects, we found an association between the 119 
degree of reduction of CBF at sleep onset and the development of CSA during sleep 120 
at high altitude (3900m).(6)  In subsequent experiments at 5050m, we demonstrated 121 
a significant association between the reduction of CBF by oral indomethacin (Indo) 122 
and the increase in CSA severity. In the same series of experiments we were able to 123 
increase CBF by administering intravenous (iv) acetazolamide (Az), which markedly 124 
reduced the severity of CSA.  Unfortunately the interpretation of those results was 125 
complicated by a concomitant rise in PaCO2 of 3 mmHg.(10)  Those observations 126 
generated our current hypothesis that changes in CBF play an important role in the 127 
pathophysiology of CSA at high altitude by altering the background stimulation of the 128 
central chemoreceptors.   Although we clearly acknowledge the important role of the 129 
peripheral chemoreceptors(26), the main aim of this experiment was to test this 130 
hypothesis via the pharmacological manipulation of CBF in normal volunteers and 131 
assess its importance in the pathophysiology of CSA at high altitude. 132 
  133 
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MATERIALS AND METHODS 134 
Eleven healthy Caucasian adults usually residing at sea level (eight males 135 
and three females), with a mean age of 31 ± 7 years (mean ± SD) and body mass 136 
index of 25.6 ± 3.6 kg/m2 completed the study, which was approved by the University 137 
of British Columbia Ethics Committee and the Nepal Health Medical Research 138 
Council and conformed to the standards set by the Declaration of Helsinki.  Written 139 
informed consent was obtained.  Other experiments were conducted on the same 140 
expedition before and after these experiments, hence the subject numbers are not 141 
continuous but are identical in all experiments from the same expedition.  However, 142 
there was no overlap with the sleep experiments or any confounding 143 
pharmacological manipulation or exercise. 144 
Experimental design and ascent profile 145 
High altitude exposure was chosen as a model for investigating the 146 
pathophysiology of CSA, because it is reproducible, relatively stable over at least 147 
one month, and can accommodate a large number of subjects in and around a 148 
stable laboratory site over a period of several weeks. 149 
All participants underwent full medical screening, including 12-lead ECG and 150 
echo-cardiography assessment.  Participants were not taking any medication, all 151 
were non-smokers, and none had any history of cardiovascular, cerebrovascular, or 152 
respiratory disease.  In addition, only two participants had previous high altitude 153 
experience, which was >4 years previous to this expedition.  15 subjects were 154 
recruited initially to these experiments.  All by general invitation to graduate students 155 
within the Dept of Physiology, University of British Columbia, Kelowna.  Two 156 
withdrew during the course of the experiments due to illnesses unrelated to the 157 
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9 
experimental methods, one subject had incomplete data collections and one 158 
withdrew to accompany another subject during an aeromedical evacuation.  (3m/1F 159 
– mean age 31, BMI =23.3). 160 
All studies were conducted at 5050m (Pb = 413).  However, familiarisation 161 
was conducted one month earlier at low altitude (in Kelowna, BC, Canada; 344 m 162 
above sea level) with the protocols completed one-month before arriving in Nepal.  163 
There was no evidence of abnormal central or obstructive sleep apnea evident in 164 
their sleep studies at 334m.  Participants spent seven-days at Kathmandu (~1400 m) 165 
before flying to Lukla (2860 m).  Participants then trekked to the Ev-K2-cnr Pyramid 166 
Laboratory over a nine-day period, which included rest days at Namche Bazar (3450 167 
m) and Pheriche (4252 m).  During the first seven days, all participants used a small 168 
dose (125mg) of oral Acetazolamide(25) twice daily during the trek to help speed 169 
acclimatization (4)  and limit altitude illness.  Importantly, treatment was discontinued 170 
>24 h before reaching 5050m to allow sufficient clearance time.  The reported half-171 
life for oral acetazolamide is 10 h and this low-dose quantity has been reported to be 172 
90–100% excreted within 24 h of administration (22); this approach, therefore, was 173 
unlikely to confound our findings.  Furthermore, to avoid any confounding influence 174 
of initial AMS, experimental sessions were carried out between days 4-14 after 175 
arrival to 5,050 m. 176 
Pharmacological manipulation of cerebral blood flow: Cerebral blood flow (CBF) was 177 
altered by the administration of licensed medications: oral indomethacin (Indo) 178 
100mg; to reduce CBF, and intravenous acetazolamide (Az 10mg/kg) (31) followed 179 
by an infusion of dobutamine (Dob) at 2-5 ug/kg/min to increase CBF.  The 180 
combination of one dose of intravenous Az followed by an infusion of Dob is an 181 
original one which was arrived at by trial and error in Australia in 2011, which 182 
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involved testing several agents alone and in combination on the investigators before 183 
settling on Az+Dob.  The theory is that Az paralyses the central arteries, preventing 184 
auto-regulation of CBF, and the Dob by increasing cardiac output increases CBF.  185 
Why PaCO2 does not change with the combination is not known, but it might be that 186 
the slight metabolic acidosis seen with the combination (table 1) caused additional 187 
hyperventilation, which reduced PaCO2 to the placebo value. 188 
 189 
Indomethacin, at a dose of 100 mg orally, reduces CBF and its reactivity by 20-40% 190 
within 90 minutes, for up to 4 hours.(31)  Intravenous Az can increase CBF by 20-191 
50% within 30 minutes, for up to 8 hours (10).  It has very different effects to oral Az.  192 
For example, when administered intravenously the effects are predominantly on CBF 193 
and extra renal carbonic anhydrase, and it does not induce measurable metabolic 194 
acidosis within this time (eg., <5 hours).  Using these pharmacological agents on 195 
different days, in a randomized fashion (toss of coin for first drug allocation, then 196 
alternate allocation), we altered CBF in both directions, and examined the result of 197 
altering CBF on the severity of CSA and the potential underlying mechanisms (eg. 198 
alterations in ventilatory responses and blood gases).  Indomethacin or placebo was 199 
administered orally approximately 90 minutes before testing began with 20 ml of an 200 
antacid solution, and Az+Dob or 0.9% saline was administered intravenously 30 201 
minutes before testing began.  The data were collected and analyzed as “control”, 202 
“drug 1” or “drug 2”.  203 
Figure 1 shows the overview of the experimental design; it should be noted that 204 
there was a 2 day “washout” after the first drug administration before the control 205 
night studies were performed. There was then another one day until the second drug 206 
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was administered (i.e., a minimum of three days between pharmacological 207 
interventions). In addition, placebo controls were used to account for possible 208 
indirect effects of the medications.  The placebo for Indo was an empty 209 
“indomethacin” gelatin capsule refilled with sugar, while normal saline was used as 210 
the intravenous Az+Dob placebo. 211 
Sleep studies 212 
All sleep studies were carried out with a Compumedics portable system (Somté 213 
PSG; Melbourne, Australia).  Participants were set up for the polysomnogram by 214 
experienced polysomnography technologists according to standard format, as 215 
described in detail elsewhere (7, 8).  Four studies were carried out simultaneously 216 
with real time data acquisition and monitoring.  All studies were scored post hoc by 217 
the same certified polysomnography technologist, who was not part of the expedition 218 
and who was blinded as to the nature of the study, using standard definitions.(1, 2)  219 
The first three to four hours of sleep were used for analysis of the drug effects 220 
because the duration of action of Indo may be only four hours after onset (tested 221 
during pilot work).  It was intended to use the first 4 hrs of sleep, however some 222 
subjects woke after 3 hrs complaining of discomfort, (equipment or beds), and were 223 
unable to return to sleep before the 4hr time limit. 224 
 225 
Experimental procedures 226 
The ventilatory response (VR) testing was performed in the afternoons and 227 
the sleep studies commenced approximately six hours later. All procedures were 228 
performed with participants lying in a supine position. 229 
Following 10-15 min of quiet rest, each experimental testing session 230 
comprised of: a) an arterial blood gas sample, b) instrumentation, c) 5-min resting 231 
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baseline, including measurement of volumetric CBF, d) modified hyperoxic 232 
hypercapnic rebreathing (HCVR) and poikilocapnic hypoxia (HVR; see details of 233 
methods below), e) drug intervention / placebo, f)  90 min rest, g) repeat testing of a-234 
d.  After a delay of approximately six-hours, subjects received another dose of drug 235 
and placebo 90 and 30 minutes prior to being put to bed for a night of full 236 
polysomnographic monitored sleep (figure 1).  237 
For the central chemoreflex magnitude (HCVR), hyperoxic hypercapnia was 238 
intentionally used in order to eliminate the influence of hypoxic-induced peripheral 239 
chemoreceptor activation at high altitude and acutely remove the influence of 240 
hypoxia on cerebrovascular tone.  The modified hypercapnia rebreathing protocol 241 
was preceded by a 5-min period of voluntary hyperventilation, in accordance with the 242 
standardized protocol of Duffin (14).  For the peripheral chemoreflex magnitude, the 243 
HVR was assessed by a two-point steady-state test which measured ventilation at 244 
ambient air and after breathing an FIO2 = 0.38 for 10 minutes (approximately 245 
equivalent to the inspired PO2 in Kelowna).  The order of the steady-state (HVR) and 246 
modified rebreathing tests (HCVR) was randomized between participants, but was 247 
consistent within participants across all trials and pre and post intervention, and full 248 
recovery (5-min) was permitted between each trial to restore end-tidal gases to 249 
baseline resting values.   250 
Due to equipment limitations, only 4 participants were studied each night.  251 
Therefore, it took 3 consecutive nights to study all 11 participants at each time point.  252 
All ventilatory testing was completed in the afternoon, and participants were 253 
instructed to avoid caffeine, alcohol and exercise in the 12 hours prior to 254 
experimental testing. 255 
Extracranial ultrasound of blood flow in conduit vessels 256 
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Continuous diameter and blood flow recordings in the left internal carotid 257 
artery (ICA), and right vertebral artery (VA) were obtained using a 10-MHz 258 
multifrequency linear array probe attached to a high-resolution ultrasound machine 259 
(Terason 3000TM, Teratech, Burlington, MA).  Imaging of the extracranial arteries 260 
was conducted during the 5-min resting baseline period. The ICA blood flow 261 
measures were recorded at least 2 cm from the carotid bifurcation, whilst ensuring 262 
there was no evidence of turbulent or retrograde flow.  The VA was measured within 263 
1 cm either proximal or distal (but at the same location within each subject) to the 264 
transverse process of C3.  Average diameter and blood flow recordings were made 265 
from a minimum of 10 cardiac cycles (see below), and care was taken to ensure 266 
probe position was stable so that the angle of insonation did not vary from 60º.  The 267 
sample volume was positioned in the centre of the vessel and adjusted to cover the 268 
width of the vessel diameter.  Measurement settings for each extracranial artery 269 
within an individual were standardised for each VR test and all within individual 270 
measures were done by the same sonographer (i.e., pre and post for both 271 
interventions). 272 
 All extracranial vascular images were directly stored as a DICOM file for 273 
offline analysis.  As described in depth elsewhere (27), analysis involved continuous 274 
measurements of arterial diameter synchronous with measurements of blood velocity 275 
at 30 Hz performed using an off-line custom-designed edge-detection and wall 276 
tracking software. Reproducibility of diameter measurements using this software is 277 
significantly better than manual methods as it reduces observer error 278 
significantly(27).  Volumetric global cerebral blood flow (gCBF) was calculated by: 279 
gCBF (ml.min-1) = (QICA . 2) + (QVA . 2) 280 
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Where QICA is the blood flow from the ICA and QVA is the blood flow in the 281 
VA.  The combined total of QICA and QVA therefore is the estimated global CBF 282 
assuming a symmetrical blood flow of contralateral ICA and VA arteries (18, 27). 283 
The measurements were made by experienced sonographers blinded to the 284 
drug administration (MHT, KS, NL). 285 
Ventilatory response testing 286 
Modified hyperoxic rebreathing method (HCVR): Participants wore a nose clip and 287 
breathed through a mouthpiece connected to a T-valve, which allowed switching 288 
from room air to a 8-L rebreathing bag filled with 7% CO2 and 93% O2.  Following 289 
baseline data collection, participants were instructed to hyperventilate for 5 minutes 290 
to lower and then maintain a partial pressure of end-tidal CO2 (PETCO2) at 22 ± 2 mm 291 
Hg (at low altitude), and 17 ± 2 mm Hg (at high-altitude).  Participants were then 292 
switched to the rebreathing bag at the end of expiration and were instructed to take 293 
three deep breaths to ensure rapid equalization of PCO2 in the rebreathing circuit.  294 
The rebreathing test was terminated when either: i) PETCO2 reached 60 mm Hg; ii) 295 
partial pressure of end-tidal O2 (PETO2) dropped below 160 mm Hg; iii) ventilation (VE) 296 
exceeded 100 L min-1, or iv) the participant reached the end of their tolerance. 297 
 The rebreathing data were analyzed on a breath-by-breath basis using a 298 
specially-designed programme (Full Fit Rebreathing programme, Version 3.1, 299 
University of Toronto, Toronto, Canada).  In brief, the initial 3-breath equilibration, 300 
sighs, swallows and aberrant breaths were excluded from analysis.  Next, the 301 
breath-by-breath PETCO2 values were plotted against time and fitted with a least 302 
squares regression line to minimise inter-breath variability (27).  Subsequently, VE 303 
was plotted against the predicted PETCO2 obtained by the regression analysis.  304 
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The VE plot was fitted with a model made up of the sum of two segments 305 
separated by a breakpoint. (27)  The first segment was taken from resting VE 306 
following equilibration with the rebreathing circuit. Thereafter, VE increased in 307 
conjunction with the predicted PETCO2.  Since hyperoxia (PaO2 ≥ 150 mm Hg) 308 
diminishes peripheral chemoreceptors output (9), the observed breakpoint was taken 309 
as the ventilatory recruitment threshold of the central chemoreflex, while the slope of 310 
the second segment was assumed to be the ventilatory CO2 sensitivity (or gain) 311 
attributed primarily to the central chemoreflex.  312 
Poikilocapnic hypoxia (HVR): Participants wore a nose clip and breathed through a 313 
mouthpiece connected to a two-way, T-shaped non-rebreathing valve that allowed 314 
switching from room air to a circuit consisting of a 200 L Douglas bag containing 315 
38% oxygen.  The protocol began with baseline room air breathing for five-minutes, 316 
before participants were switched to the 38% oxygen circuit for 10-minutes.  The 317 
38% oxygen was used to passively normalize inspired PO2 back to sea level values.    318 
This was done to allow comparison with earlier sea level studies, (data in 319 
preparation). 320 
 The mean VE over the last five-minutes of oxygen breathing was used as one 321 
data point and the mean resting (room air) ventilation as the other.  The slope of the 322 
delta VE vs. delta SpO2 joining line was taken as the HVR. 323 
Respiratory variables:  Inspiratory flow was measured using a heated pneumotach 324 
(Hans-Rudolph 3813), attached to the mouthpiece (via a disposal filter).  Partial 325 
pressures of end-tidal CO2 and O2 were sampled from a needle inserted into the 326 
mouthpiece, dried with nafion tubing and dessicant, and measured using a dual CO2 327 
and O2 gas analyzer (ML206, ADInstruments, Australia).  Gases were measured in 328 
percent and converted to mm Hg (BTPS) using the ambient atmospheric pressure.  329 
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Minute ventilation and gas values were displayed in real time during testing 330 
(PowerLab, ADInstruments).  Prior to each testing session, the pneumotachometer 331 
was calibrated using a 3-L syringe (Hans-Rudolph 5530) and the gas analyzers were 332 
calibrated using known concentrations of CO2 and O2. 333 
 Cardiovascular and respiratory variables were measured continuously at 200 334 
Hz using an analog-to-digital converter (Powerlab 16/30 ML880; ADInstruments), 335 
interfaced with a computer, and were subsequently analyzed using commercially 336 
available software, (LabChart v7, ADInstruments). 337 
Blood gases. Arterial blood variables [pH, partial pressure of arterial O2 (PaO2), 338 
partial pressure of arterial CO2 (PaCO2), arterial O2 saturation (SaO2), bicarbonate 339 
concentration [HCO3
-], and haematocrit (Hct)] from the radial artery (occasionally 340 
femoral artery) were obtained after 10-min supine rest using a 23 or 25-gauge 341 
needle into a preheparinised syringe.  Following standardized calibration, all blood 342 
samples were analyzed using an arterial blood-gas analyzing system (ABL-90 Co-343 
Ox, Radiometer, Copenhagen, Denmark). 344 
Statistical Analysis 345 
Data Sets:  There were complete data sets for the collected variables for CBF, ABGs 346 
and PSG data; however the ventilatory response test data was incomplete.  There 347 
were 2 empty cells from 44 in the HVR and HCVR results before and after Indo.  All 348 
results were analyzed using SPSS software (v23. IBM Corp. Ireland).  The Shapiro-349 
Wilks test was used to test for distribution normality in each data set.  Data sets that 350 
were normally distributed were analyzed by paired t-test (most data).  Data sets not 351 
normally distributed (ie. Pre Az/Dob CBF, Pre Az/Dob PaO2, Post Indo BE, Mean 352 
control AHI, and all HCVR data), were analyzed with their data pairs by a non-353 
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parametric test (Wilcoxon Sign Rank Test)(23).  The AHI data were analyzed by 354 
repeated measures ANOVA with post hoc Bonferroni tests between conditions. 355 
 356 
The correlations shown in Table 2 were performed using Pearson’s and Spearman’s 357 
methods (23) in SPSS v23.  Pearson’s correlation method was used for the normally 358 
distributed data.  Spearman’s method was used when any of the input data was not 359 
normally distributed, [all correlations with hypercapnic ventilatory responses (HCVR)] 360 
and those correlations using data from baseline cerebral blood flow (CBF) prior to 361 
Az+Dob, [ie change in cerebral blood flow (Δ CBF post Acetazolamide)]. 362 
  363 
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RESULTS 364 
EFFECTS OF ACETAZOLAMIDE+DOBUTAMINE AND INDOMETHACIN  365 
Acetazolamide+dobutamine 366 
Acute intravenous administration of acetazolamide (Az) followed by a continuous 367 
intravenous infusion of dobutamine (Dob) (2-5 ug/kg/min) increased awake resting 368 
CBF by 37% (95%CI: 28-46%; P< 0.001; Table 1. figure 2A), while the apnea-369 
hypopnoea index (AHI) that night was 65% (-80% to -50%)(figure 3A) lower than 370 
control (P=0.001; table 1).  During Az+Dob administration, PaCO2 was unchanged 371 
from pre administration.  However there was a non-significant fall in pH (P>0.05; 372 
table 1) due to the development of a slight metabolic acidosis.  Base excess (BE) 373 
increased from -4.8±1.7 to -7.0±2.8 (P<0.05). 374 
The HVR, did not significantly change after the administration of Az+Dob 375 
(figure 5A).  The slope of the HCVR fell from 5.9 ± 2.7 to 4.2 ± 2.8 l/min/mmHg. (P= 376 
0.1; table 1, figure 4A). 377 
The arousal index was reduced from 68 ± 47/hr on the control night to 22 ± 378 
10/hr (P < 0.01 table 1).  There was no change in sleep efficiency, or total sleep time. 379 
Indomethacin 380 
Ninety minutes following the oral administration of indomethacin (Indo), 381 
awake resting CBF was reduced by 21% (95%CI: 16-26%), while the mean AHI 382 
during sleep was not significantly altered (see table 1, figures 2B and 3B).  The 383 
PaCO2 did not change from 26  3 mm Hg (see table 1); yet metabolic alkalosis was 384 
still observed, with the pH rising slightly from 7.46±02 to 7.48±02 (P=NS; table 1).   385 
Although the HVR did not increase significantly following Indo (figure 5B), the 386 
HCVR was increased by 1.5 l/min/mmHg (P=0.05; table 1, figure 4B).  The mean % 387 
increase was 23% (95%CI: 2-44%). 388 
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There was no change in sleep efficiency, nor total sleep time.   389 
Correlations 390 
Table 2 shows the correlation co-efficients for the relevant respiratory variables 391 
following the administration of the two drugs and the potential influence that each 392 
had with the severity of AHI. 393 
 394 
DISCUSSION 395 
Herein, we report the results of what we believe to be only the second attempt 396 
to artificially manipulate CBF in the field, in the midst of two weeks of acclimatization 397 
to an altitude of 5,050 m above sea level, in a group of otherwise healthy volunteers.  398 
Both drug interventions were effective in altering CBF.  The novel combination of 399 
intravenous acetazolamide plus dobutamine infusion significantly reduced the 400 
severity of CSA, but on this occasion was not associated with a significant change in 401 
PaCO2, as occurred in our previous study(10) that confounded interpretation of those 402 
data. The Indo administration on the other hand, appears to have had only one 403 
unintended effect; CSA severity was unaltered, probably because the AHI was 404 
already at, or near, its theoretical maximum.  The mean CSA index in these 405 
experiments was 140/hr compared to 89/hr for the ‘control night’ comparison used in 406 
the previous study (10).  The other findings, and relevant methodological 407 
considerations, are outlined below.   408 
 409 
We recognized that acclimatization would be ongoing throughout the duration 410 
of our study(9), and adjusting for its effects would be important in the conduct of 411 
experiments and in the interpretation of the results of the current study.  This was 412 
achieved by obtaining new arterial blood gas samples, ventilatory response and CBF 413 
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measurements immediately prior to each drug intervention, and randomly allocating 414 
the order of the drug administration to either side of a control night study.  Each drug 415 
was equally administered pre and post the control night. 416 
Central sleep apnea at high altitude occurs during light sleep (Stages 1 and 2 417 
NREM sleep), in the presence of relative hypocapnia and alkalosis at sleep onset 418 
(12).  Although many studies cite the classic Lahiri study (17) to provide evidence of 419 
the relationship between the magnitude of HVR and periodic breathing, this 420 
relationship was largely created by the inclusion of a Sherpa group with a blunted 421 
HVR. However, there was no obvious relationship between HVR and periodic 422 
breathing within the lowlander population. This absence of a relationship between 423 
HVR was further confirmed, albeit in a subgroup (n=5), at 6300 and 8050 m (29). 424 
These findings are consistent with Masuyama et al (20), who found that two of nine 425 
mountaineers did not develop CSA at altitude despite normal values for HVR (20). 426 
More recently, we have also reported an absence of a relationship between HVR 427 
and periodic breathing at 5050 m (9). In contrast, at 4400 m in a small sample size 428 
(n=4) it was shown that the respiratory stimulant almitrine doubled the HVR and 429 
elevated periodic breathing compared with Az or placebo (15). A number of potential 430 
explanations exist for these discrepant and variable findings, including:  (a) evidence 431 
that the hypoxic and CO2 response are not always similar above and below eupnea 432 
(11), (b) differences in awake vs. sleep respiratory control, (c) variable acid-base 433 
status, and (d) methodological differences (e.g., chemoreflex testing, natural vs. 434 
simulated altitude, etc.). Nevertheless, collectively these findings highlight the multi-435 
factorial complexity of periodic breathing at high altitude. 436 
 437 
Influence of cerebral blood flow on CSA severity and ventilatory responses 438 
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Intravenous Az+Dob caused a 37% increase in global CBF.  This increase 439 
was associated with a 65% reduction in AHI.  Our hypothesis was that this would be 440 
due to a reduction in central chemoreceptor stimulation by locally produced CO2, 441 
because of increased clearance caused by the higher CBF.  Mean HCVR was 442 
lowered by the Az+Dob by 28% (P=0.1). In support of a putative link between 443 
chemoreflex drive and CBF, correlational analysis revealed a modest correlation 444 
(r=0.41 P=0.054) between the change in HCVR compared to the change in CBF 445 
after intravenous Az+Dob, and change in HCVR and change in CBF (r=0.48,  446 
P=0.19) after Indo. (see table 2). Crucially, with our combined pharmacological 447 
interventions to increase CBF there was no change in PaCO2, or pH, in contrast to 448 
our previous study (10). 449 
Oral Indo administration resulted in a 21% (95%CI: 16-26%) reduction in CBF 450 
and increased HCVR by 23% (95%CI: 2-44% P=0.05).  This was associated with no 451 
significant change in AHI, unlike our earlier study (10) at the same altitude.  On this 452 
occasion, there was no change in PaCO2 or pH.  Most subjects had little or no 453 
change from their very high values for AHI prior to drug administration (AHI >100/hr), 454 
which suggests that they were perhaps already close to their maximum values for 455 
AHI. (10)  These experiments were conducted after a longer period of acclimatization 456 
at 5,050 metres, leading to a markedly elevated central AHI. 457 
Theoretically a reduction in the length of the apneas below 10 seconds in 458 
duration, could cause a reduction in the scored events and hence CSA index. 459 
Similarly, because CSA occurs predominantly in stage 2 NREM sleep, an increase in 460 
stable breathing could also cause a reduction in CSA index. Those mechanisms 461 
were not present in these experiments: the reduction in CSA index was due to a 462 
marked reduction in events not a shortening of apneas to below the 10 second 463 
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scoring threshold. The percentages of stable breathing [Slow Wave Sleep (NREM3) 464 
together with REM sleep] were not altered. 465 
The increase in CBF using intravenous Az plus Dob infusion dramatically 466 
reduced CSA.  In these experiments, as compared to our earlier experiments where 467 
CBF was increased by iv acetazolamide only, the interpretation of that outcome has 468 
not been confounded by an increase in PaCO2 (and presumably brain PCO2), so the 469 
interpretation can be made more confidently. 470 
 471 
Limitations 472 
The major limitation of this study was that the study group comprised only 11 473 
subjects; however, our data are broadly consistent with recent data from our earlier 474 
studies at this altitude(10), as well as Block et al (5) and earlier data from Salvaggio 475 
et al(24).  Other limitations included: The inclusion of subjects in the study group with 476 
generally lower ventilatory responses and low control AHI values increased the 477 
variability in the data, especially ventilatory response data.  Due to time constraints 478 
there was no true control group in our study.  Instead, approximately in the middle of 479 
the two weeks acclimatization at 5050m, in randomized order, CBF was artificially 480 
increased and decreased by drug administration. Post hoc analysis revealed exactly 481 
equal dispersion over time, between the two interventions within the recorded 482 
acclimatization period.  483 
We studied only the first three to four hours of sleep because of the limited 484 
duration of effect of the indomethacin, which is approximately 4 hours(31).  We have 485 
previously confirmed this time course by post hoc observation on other subjects (10) 486 
and during pilot testing in our laboratory. 487 
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While there are a number of meaningful ways to assess the HVR at sea level using 488 
steady-state (isocapnic hypoxia) or rebreathing methods (hyperoxic vs hypoxic 489 
rebreathing), at high altitude the methodological approach becomes even more 490 
complex (14, 21, 26), and consensus on the best approach has not been reached.  491 
Further, it is known that steady-state techniques produce higher values for HVR than 492 
non steady-state techniques (19).  Nevertheless, we chose a steady-state test so 493 
that we could match inspired PO2 values between the low altitude control and high 494 
altitude studies.  As this was a within-subjects design we did not need to correct 495 
HVR for vital capacity or FEV1(28), which has been suggested by others to improve 496 
the test. 497 
 498 
CONCLUSION 499 
The findings of the present study highlight an important role for CBF in CSA 500 
severity at high altitude, although the mechanisms of action cannot be ascertained 501 
from our data.  There was a highly significant reduction in CSA severity with 502 
Acetazolamide+Dobutamine administration, and a suggestion of a relationship 503 
between the reduction in HCVR and the increase in CBF with the same intervention, 504 
however, there was no significant correlation between change in either CBF or 505 
HCVR and AHI with Az-Dob.  That may be due to a type 2 error due to the reduced 506 
subject numbers.  Reducing CBF with indomethacin did not affect AHI in this study, 507 
probably because the AHI was already at or near its maximal possible value. 508 
  509 
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Table 1: The effects of intravenous Acetazolamide + Dobutamine and oral 529 
Indomethacin on the key sleep and respiratory variables. 530 
 Pre 
Acetazolamide 
+ Dobutamine 
Post 
Acetazolamide 
+ Dobutamine 
Pre 
Indomethacin 
Post 
Indomethacin 
Global CBF 
(ml/min) 
526±110  718± 120** 546±64 430±51 *** 
AHI  (event/hr) 140± 45 48 ± 37*** 140 ± 45 123 ± 30 
Arousal Index 
(event/hr) 
68 ± 47 22 ± 10** 68 ± 47 60 ± 36 
PaO2  (mmHg) 42  2 44  4 42  4 44  4 
PaCO2  
(mmHg) 
25  3 25  3 26  2 26  3 
pH 7.48  .02 7.45  .03 7.46  .02 7.48  .02 
BE -4.8  1.7 -7.0  2.8* -5.2  1.7 -4.5  1.8 
HCVR 
(L/min/mmHg) 
5.9 ± 2.7 
n=11 
4.2 ± 2.8# 
n=11 
6.4 ± 4.2 
n=11 
7.9 ± 6.0* 
n=11 
HVR 
(L/min/%SpO2) 
0.3 ± 0.16 
n=11 
0.3 ± 0.20 
n=11 
0.31 ± 0.14 
n=10 
0.33 ± 0.20 
n=10 
 531 
Pre drug value for AHI are from the control night sleep studies. All other control 532 
values recorded immediately before intervention. 533 
* P<0.05; **P<0.01; ***P ≤ 0.001; #  P = 0.1 534 
  535 
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Table 2: The correlations between key Cerebral Blood Flow, sleep and respiratory 536 
variables. 537 
Inputs Post Acetazolamide Post Indomethacin 
 r value P value r value  P value 
AHI / CBF -0.27 0.48 0.05 0.90 
AHI / HCVR* -0.30 0.37 -0.39 0.24 
AHI / PaCO2 -0.16 0.64 -0.21 0.55 
AHI / HVR -0.55 0.08 0.23 0.52 
AHI / pH -0.10 0.77 -0.25 0.45 
AHI / PaO2 -0.20 0.55 -0.02 0.96 
Δ AHI / Δ HVR -0.04 0.92 0.22 0.55 
Δ AHI / Δ HCVR* -0.20 0.56 0.17 0.76 
Δ HCVR / Δ CBF* 0.41 0.054 0.48 0.19 
Δ HVR / Δ CBF* -0.01 0.78 0.66 0.07 
Δ AHI / Δ CBF* 0.14 0.98 -0.20 0.60 
AHI = Apnea-Hypopnoea Index (events/hr sleep) 538 
HCVR = Hypercapnic Ventilatory Response (L/min/mmHg) 539 
HVR = Hypoxic Ventilatory Response (L/min/%SpO2) 540 
Δ AHI = Change in Apnea-Hyperpnea Index 541 
Δ HVR = Change in Hypoxic Ventilatory Response 542 
Δ HCVR = Change in Hypercapnic Ventilatory Response 543 
Δ CBF = Change in Cerebral Blood 544 
r-value = Pearson or Spearman correlation co-efficient 545 
*  = Spearman correlation method.  All other correlations tested by Pearson method. 546 
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Figure 1: An overview of the experimental design indicating the sequence of testing 
 
 
INDO = Indomethacin 
ACZ = Acetazolamide 
DOB = Dobutamine 
ABG = arterial blood gas measurement 
CBF = cerebral blood flow 
VRs = ventilatory response testing 
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Figure 2: Panel A: The effect of intravenous Az+Dob on CBF. 
 Panel B: The effect of oral Indo on CBF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*** = P < 0.001 
gCBF = global Cerebral Blood Flow 
Az = Acetazolamide 
Dob = Dobutamine 
Indo = Indomethacin 
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Figure 3:  Panel A: The effect of intravenous Az+Dob on apnea-hypopnea index. 
 Panel B: The effect of oral Indo on apnea-hypopnea index. 
 
 
 
 
 
 
 
 
 
 
  
 
*** = P < 0.001 
NS = Non significant 
AHI = Apnea-hypopnea index 
Az = Acetazolamide 
Dob = Dobutamine 
Indo = Indomethacin 
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Figure 4:  Panel A. The effect of intravenous Az+Dob on HCVR. 
 Panel B: The effect of oral Indo on HCVR. 
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Figure 5:  Panel A: The effect of intravenous Az+Dob on HVR. 
 Panel B: The effect of oral Indo on HVR. 
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